Aurobindo Pharma has announced an ₹800-crore buyback at ₹1,475 per share, with April 17, 2026 set as the record date—meaning investors must buy shares before this date to be eligible.Read More
Going forward, the 24,250–24,300 zone is likely to act as a crucial resistance band. A decisive move above this range could trigger a rally towards 24,750–24,800. On the other hand, failure to break above 24,300 convincingly may lead to renewed selling pressure in the market.Read More
Trump, according to news reports, said that the US-Iran peace talks could resume in Islamabad over the next two days following the breakdown of negotiations over the weekend. Earlier, the US said its navy had blockaded traffic to and from Iranian ports in response to Iran’s disruption of shipping through the Strait of Hormuz.Read More
SEBI has allowed companies to revise IPO fresh issue sizes by up to 50% without refiling a draft offer document, according to sources. The move aims to ease capital raising in volatile markets. Currently, firms must refile if the issue size changes by more than 20% from the original plan.Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.
